Innocan Pharma Corp (INNO.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 9 | 10 | 10 | 8 | 9 |
| Accounts receivable | 18 | 541 | -542 | -147 | -21 |
| Accounts payable and accrued liabilities | -257 | -88 | 365 | -221 | 156 |
| Other Working Capital | -1,158 | 315 | -408 | -293 | -112 |
| Other Operating Activity | 385 | -103 | -172 | -658 | -750 |
| Operating Cash Flow | $-1,003 | $675 | $-747 | $-1,311 | $-718 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -6 | -3 | -2 | -9 | -1 |
| Other Investing Activity | 0 | 0 | 0 | 0 | -31 |
| Investing Cash Flow | $-6 | $-3 | $-2 | $-9 | $-32 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -6 | -5 | -5 | -5 | -5 |
| Common Stock Issued | 395 | 0 | 619 | 584 | 762 |
| Other Financing Activity | 470 | 0 | 836 | 539 | 691 |
| Financing Cash Flow | $859 | $-5 | $1,450 | $1,118 | $1,448 |
| Exchange Rate Effect | 18 | -73 | 9 | 63 | -47 |
| Beginning Cash Position | 5,189 | 4,595 | 3,885 | 4,024 | 3,373 |
| End Cash Position | 5,057 | 5,189 | 4,595 | 3,885 | 4,024 |
| Net Cash Flow | $-150 | $667 | $701 | $-202 | $698 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,003 | 675 | -747 | -1,311 | -718 |
| Capital Expenditure | -6 | -3 | -2 | -9 | -1 |
| Free Cash Flow | -1,009 | 672 | -749 | -1,320 | -719 |